

SPARTA Doublet: A Phase 2, Randomized, Double-Blind (Subject- and Investigator-Blind, Sponsor-Open), Placebo-Controlled Trial to Investigate the Safety, Tolerability, and Efficacy of ACH-0143422 in Combination with ACH-0143102 for 12, 8, or 6 Weeks in Treatment-Naive Subjects with Chronic Hepatitis C

ACTRN12615000390583

Status	WITHDRAWN
Phase	Phase 2
Sponsor	Achillion Pharmaceuticals, Inc
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (8)

- Males and females aged 18 years and less than 70 years.
- Chronic Hepatitis C infection
- Genotype 1 infection
- HCV RNA more than or equal to 10,000 IU/mL at screening
- No clinically relevant health abnormalities
- ... and 3 more (see full listing online)

Exclusion (6)

- BMI of more than 36.0 kg/m².
- Pregnant or nursing females
- Participation in any clinical trial within 30 days prior to study drug administration.
- Previous treatment (defined in the protocol)
- Previous use of certain medication (defined in protocol)
- ... and 1 more (see full listing online)

Locations (1 total)

New Zealand